Embecta Corp.
Financials
Valuation Metrics
Embecta Corp.'s Market Cap is $221M. At end of 2025 it was $683M. Ranked #3021 of 3,112 in US market (top 97%), #1370 of 1,445 on NASDAQ (top 95%), #194 of 206 in Health Care Equipment & Services (top 94%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $221M | US#3,021/3,112 Sec#194/206 |
| Revenue | $1.04B | US#1,912/3,112 Sec#115/206 |
| Net Income | $112M | US#1,559/3,112 Sec#76/206 |
| Total Assets | $1.03B | US#2,433/3,112 Sec#127/206 |
| Net Assets | $551M | US#2,187/3,112 Sec#113/206 |
| Employees | 1,850 | US#1,143/3,112 Sec#93/206 |
| Value | ||
| P/E | 1.97x | US#10/3,112 Sec#1/206 |
| P/B | 0.40x | US#46/3,112 Sec#1/206 |
| P/S | 0.21x | US#84/3,112 Sec#7/206 |
| EV/EBITDA | 4.32x | US#110/3,112 Sec#3/206 |
| FCF Yield | 92.75% | US#11/3,112 Sec#1/206 |
| Profitability | ||
| ROE | 20.33% | US#565/3,112 Sec#26/206 |
| ROA | 10.87% | US#394/3,112 Sec#21/206 |
| Op. Margin | 29.78% | US#454/3,112 Sec#12/206 |
| Revenue Growth | -14.36% | US#2,722/3,112 Sec#198/206 |
| Earnings Growth | -117.45% | US#2,120/3,112 Sec#106/206 |
| Financial Health | ||
| Debt Ratio | 300.71% | US#2,118/3,112 Sec#176/206 |
| Total Debt | $1.36B | US#1,327/3,112 Sec#70/206 |
| FCF | $205M | US#1,345/3,112 Sec#82/206 |
| Cash | $185M | US#1,784/3,112 Sec#109/206 |
| Current Ratio | 2.46x | US#1,010/3,112 Sec#100/206 |
| Net Debt/EBITDA | 3.64x | US#1,801/3,112 Sec#114/206 |
| Dividend | ||
| Div. Yield | 15.99% | US#23/3,112 Sec#1/206 |
| Div. Growth | 1.68% | US#1,088/3,112 Sec#39/206 |
| Payout Ratio | 25.42% | US#8/3,112 Sec#2/206 |
| Performance | ||
| 1Y Return | -61.21% | US#3,047/3,112 Sec#199/206 |
| 1M Return | 11.04% | US#471/3,112 Sec#43/206 |
| From 52W High | -75.41% | US#3,063/3,112 Sec#204/206 |
| 1Y MDD | -80.53% | US#3,049/3,112 Sec#201/206 |
| Trading | ||
| Volume | 1,105,387 shares | US#1,390/3,112 Sec#92/206 |
| Trading Value | $4M | US#2,729/3,112 Sec#177/206 |
| Per Share | ||
| EPS | $2.36 | US#1,152/3,112 Sec#61/206 |
| BPS | $-10.35 | US—/3,112 Sec—/206 |
Company Info
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.